A similar increase in phospho-ERK1/2 but not phospho-AKT level was observed in both acquired and intrinsically resistant ovarian cancer cells post cisplatin-paclitaxel treatment at the protein level (FigS3B). Here, AKT1 is linked to ovarian carcinoma.